Last reviewed · How we verify
Bupivacaine Injectable Solution
At a glance
| Generic name | Bupivacaine Injectable Solution |
|---|---|
| Sponsor | The Cooper Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery (NA)
- The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology (NA)
- Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition (PHASE4)
- Postop Pain Management in Pituitary Tumour Patients (PHASE4)
- Effect of Paracervical Block on Postoperative Pain After vNOTES Uterosacral Ligament Suspension (NA)
- Bupivacaine for Postoperative Pain After Laparoscopic Hysterectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine Injectable Solution CI brief — competitive landscape report
- Bupivacaine Injectable Solution updates RSS · CI watch RSS
- The Cooper Health System portfolio CI